{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:07:41Z","timestamp":1790737661629,"version":"4.1.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fund of the First Hospital of Lanzhou University","award":["ldyyyn2023-87"],"award-info":[{"award-number":["ldyyyn2023-87"]}]},{"name":"Gansu Provincial University Teachers' Innovation Fund Project","award":["2025B-010"],"award-info":[{"award-number":["2025B-010"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["31960236"],"award-info":[{"award-number":["31960236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Open Fund of Gansu Key Laboratory of Microorganisms for Extreme Environments","award":["EEMRE202403"],"award-info":[{"award-number":["EEMRE202403"]}]},{"name":"Joint Scientific Research Foundation of Gansu Province","award":["23JRRA1498"],"award-info":[{"award-number":["23JRRA1498"]}]},{"DOI":"10.13039\/501100017702","name":"Lanzhou Talent Innovation and Entrepreneurship Project","doi-asserted-by":"crossref","award":["2019-RC-34"],"award-info":[{"award-number":["2019-RC-34"]}],"id":[{"id":"10.13039\/501100017702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-026-05224-z","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:25:52Z","timestamp":1780550752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of the gut microbiota\u2013bile acid axis in liver fibrosis based on microbiomics and targeted metabolomics"],"prefix":"10.1186","volume":"26","author":[{"given":"Yu-Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Zhong","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hui","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Fei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"22","key":"5224_CR1","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.3748\/wjg.v27.i22.3010","volume":"27","author":"JW Shao","year":"2021","unstructured":"Shao JW, Ge TT, Chen SZ, Wang G, Yang Q, Huang CH, et al. Role of bile acids in liver diseases mediated by the gut microbiome. World J Gastroenterol. 2021;27(22):3010\u201321. https:\/\/doi.org\/10.3748\/wjg.v27.i22.3010.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"5224_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/jhbp.245","volume":"22","author":"E Seki","year":"2015","unstructured":"Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 2015;22(7):512\u20138. https:\/\/doi.org\/10.1002\/jhbp.245.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"5224_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12967-021-02854-x","volume":"19","author":"J Cai","year":"2021","unstructured":"Cai J, Hu M, Chen Z, Ling Z. The roles and mechanisms of hypoxia in liver fibrosis. J Transl Med. 2021;19(1):186. https:\/\/doi.org\/10.1186\/s12967-021-02854-x.","journal-title":"J Transl Med"},{"issue":"8","key":"5224_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.14670\/hh-25.1075","volume":"25","author":"D Povero","year":"2010","unstructured":"Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Paternostro C, et al. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol. 2010;25(8):1075\u201391. https:\/\/doi.org\/10.14670\/hh-25.1075.","journal-title":"Histol Histopathol"},{"issue":"3","key":"5224_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s2468-1253(19)30349-8","volume":"5","author":"GC Collaborators","year":"2020","unstructured":"Collaborators GC. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245\u201366. https:\/\/doi.org\/10.1016\/s2468-1253(19)30349-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5224_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2017.05.016","volume":"121","author":"K B\u00f6ttcher","year":"2017","unstructured":"B\u00f6ttcher K, Pinzani M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv Drug Deliv Rev. 2017;121:3\u20138. https:\/\/doi.org\/10.1016\/j.addr.2017.05.016.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"5224_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/2040622315580069","volume":"6","author":"JS Pedersen","year":"2015","unstructured":"Pedersen JS, Bendtsen F, M\u00f8ller S. Management of cirrhotic ascites. Ther Adv Chronic Dis. 2015;6(3):124\u201337. https:\/\/doi.org\/10.1177\/2040622315580069.","journal-title":"Ther Adv Chronic Dis"},{"key":"5224_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev-pathol-030320-095722","volume":"16","author":"RM Jones","year":"2021","unstructured":"Jones RM, Neish AS. Gut Microbiota in Intestinal and Liver Disease. Annu Rev Pathol. 2021;16:251\u201375. https:\/\/doi.org\/10.1146\/annurev-pathol-030320-095722.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"5224_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","volume":"18","author":"R Wang","year":"2021","unstructured":"Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2021;18(1):4\u201317. https:\/\/doi.org\/10.1038\/s41423-020-00592-6.","journal-title":"Cell Mol Immunol"},{"key":"5224_CR10","doi-asserted-by":"publisher","unstructured":"Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda). 2020;35(4):261\u201374. https:\/\/doi.org\/10.1152\/physiol.00005.2020.","DOI":"10.1152\/physiol.00005.2020"},{"key":"5224_CR11","doi-asserted-by":"publisher","first-page":"775526","DOI":"10.3389\/fimmu.2021.775526","volume":"12","author":"Z Zheng","year":"2021","unstructured":"Zheng Z, Wang B. The Gut-Liver Axis in Health and Disease: The Role of Gut Microbiota-Derived Signals in Liver Injury and Regeneration. Front Immunol. 2021;12:775526. https:\/\/doi.org\/10.3389\/fimmu.2021.775526.","journal-title":"Front Immunol"},{"issue":"2","key":"5224_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/apt.14397","volume":"47","author":"CA Woodhouse","year":"2018","unstructured":"Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47(2):192\u2013202. https:\/\/doi.org\/10.1111\/apt.14397.","journal-title":"Aliment Pharmacol Ther"},{"key":"5224_CR13","doi-asserted-by":"publisher","first-page":"774335","DOI":"10.3389\/fcimb.2022.774335","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, et al. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol. 2022;12:774335. https:\/\/doi.org\/10.3389\/fcimb.2022.774335.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"5224_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","volume":"157","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, et al. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;157(4):1109\u201322. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.028.","journal-title":"Gastroenterology"},{"issue":"5","key":"5224_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25(5):1054\u201362. e5.","journal-title":"Cell Metab"},{"issue":"1","key":"5224_CR16","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1038\/s41598-020-59535-w","volume":"10","author":"TS Dong","year":"2020","unstructured":"Dong TS, Katzka W, Lagishetty V, Luu K, Hauer M, Pisegna J, et al. A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD. Sci Rep. 2020;10(1):2771. https:\/\/doi.org\/10.1038\/s41598-020-59535-w.","journal-title":"Sci Rep"},{"issue":"5","key":"5224_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","volume":"58","author":"G Kakiyama","year":"2013","unstructured":"Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949\u201355. https:\/\/doi.org\/10.1016\/j.jhep.2013.01.003.","journal-title":"J Hepatol"},{"issue":"3","key":"5224_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1096\/fj.14-259515","volume":"29","author":"M Mazagova","year":"2015","unstructured":"Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. Faseb j. 2015;29(3):1043\u201355. https:\/\/doi.org\/10.1096\/fj.14-259515.","journal-title":"Faseb j"},{"key":"5224_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fcimb.2020.00018","volume":"10","author":"S Wan","year":"2020","unstructured":"Wan S, Nie Y, Zhang Y, Huang C, Zhu X. Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice. Front Cell Infect Microbiol. 2020;10:18. https:\/\/doi.org\/10.3389\/fcimb.2020.00018.","journal-title":"Front Cell Infect Microbiol"},{"key":"5224_CR20","doi-asserted-by":"publisher","first-page":"113185","DOI":"10.1016\/j.biopha.2022.113185","volume":"151","author":"K Fu","year":"2022","unstructured":"Fu K, Ma C, Wang C, Zhou H, Gong L, Zhang Y, et al. Forsythiaside A alleviated carbon tetrachloride-induced liver fibrosis by modulating gut microbiota composition to increase short-chain fatty acids and restoring bile acids metabolism disorder. Biomed Pharmacother. 2022;151:113185. https:\/\/doi.org\/10.1016\/j.biopha.2022.113185.","journal-title":"Biomed Pharmacother"},{"key":"5224_CR21","doi-asserted-by":"publisher","first-page":"115478","DOI":"10.1016\/j.jep.2022.115478","volume":"296","author":"C Wang","year":"2022","unstructured":"Wang C, Ma C, Fu K, Liu Y, Gong L, Peng C, et al. Hepatoprotective effect of phillygenin on carbon tetrachloride-induced liver fibrosis and its effects on short chain fatty acid and bile acid metabolism. J Ethnopharmacol. 2022;296:115478. https:\/\/doi.org\/10.1016\/j.jep.2022.115478.","journal-title":"J Ethnopharmacol"},{"key":"5224_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.trsl.2019.02.005","volume":"209","author":"R Zhou","year":"2019","unstructured":"Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res. 2019;209:22\u201338. https:\/\/doi.org\/10.1016\/j.trsl.2019.02.005.","journal-title":"Transl Res"},{"key":"5224_CR23","doi-asserted-by":"publisher","first-page":"945368","DOI":"10.3389\/fcimb.2022.945368","volume":"12","author":"YL Zhang","year":"2022","unstructured":"Zhang YL, Li ZJ, Gou HZ, Song XJ, Zhang L. The gut microbiota-bile acid axis: A potential therapeutic target for liver fibrosis. Front Cell Infect Microbiol. 2022;12:945368. https:\/\/doi.org\/10.3389\/fcimb.2022.945368.","journal-title":"Front Cell Infect Microbiol"},{"issue":"48","key":"5224_CR24","doi-asserted-by":"publisher","first-page":"7603","DOI":"10.3748\/wjg.v26.i48.7603","volume":"26","author":"X Qi","year":"2020","unstructured":"Qi X, Yang M, Stenberg J, Dey R, Fogwe L, Alam MS, et al. Gut microbiota mediated molecular events and therapy in liver diseases. World J Gastroenterol. 2020;26(48):7603\u201318. https:\/\/doi.org\/10.3748\/wjg.v26.i48.7603.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"5224_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/19490976.2019.1674124","volume":"11","author":"JA Winston","year":"2020","unstructured":"Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota. Gut Microbes. 2020;11(2):158\u201371. https:\/\/doi.org\/10.1080\/19490976.2019.1674124.","journal-title":"Gut Microbes"},{"key":"5224_CR26","doi-asserted-by":"publisher","unstructured":"Hou JJ, Wang X, Wang YM, Wang BM. Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review. Crit Rev Microbiol. 2021;1\u201318. https:\/\/doi.org\/10.1080\/1040841x.2021.2018401.","DOI":"10.1080\/1040841x.2021.2018401"},{"key":"5224_CR27","doi-asserted-by":"publisher","unstructured":"Gu Y, Li L, Yang M, Liu T, Song X, Qin X, et al. Bile acid-gut microbiota crosstalk in irritable bowel syndrome. Crit Rev Microbiol. 2022;1\u201320. https:\/\/doi.org\/10.1080\/1040841x.2022.2058353.","DOI":"10.1080\/1040841x.2022.2058353"},{"issue":"2","key":"5224_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1152\/physrev.00049.2019","volume":"101","author":"A Perino","year":"2021","unstructured":"Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiol Rev. 2021;101(2):683\u2013731. https:\/\/doi.org\/10.1152\/physrev.00049.2019.","journal-title":"Physiol Rev"},{"key":"5224_CR29","doi-asserted-by":"publisher","first-page":"108238","DOI":"10.1016\/j.pharmthera.2022.108238","volume":"237","author":"J Cai","year":"2022","unstructured":"Cai J, Rimal B, Jiang C, Chiang JYL, Patterson AD. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacol Ther. 2022;237:108238. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108238.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"5224_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","volume":"15","author":"W Jia","year":"2018","unstructured":"Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111\u201328. https:\/\/doi.org\/10.1038\/nrgastro.2017.119.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"5224_CR31","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/liv.14453","volume":"40","author":"LA Adams","year":"2020","unstructured":"Adams LA, Wang Z, Liddle C, Melton PE, Ariff A, Chandraratna H, et al. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2020;40(6):1356\u201365. https:\/\/doi.org\/10.1111\/liv.14453.","journal-title":"Liver Int"},{"issue":"2","key":"5224_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/apt.15035","volume":"49","author":"C Caussy","year":"2019","unstructured":"Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, et al. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther. 2019;49(2):183\u201393. https:\/\/doi.org\/10.1111\/apt.15035.","journal-title":"Aliment Pharmacol Ther"},{"key":"5224_CR33","doi-asserted-by":"publisher","first-page":"103290","DOI":"10.1016\/j.ebiom.2021.103290","volume":"66","author":"G Xie","year":"2021","unstructured":"Xie G, Jiang R, Wang X, Liu P, Zhao A, Wu Y, et al. Conjugated secondary 12alpha-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine. 2021;66:103290. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103290.","journal-title":"EBioMedicine"},{"issue":"4","key":"5224_CR34","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1111\/jcmm.14951","volume":"24","author":"X Wang","year":"2020","unstructured":"Wang X, Chen L, Wang H, Cai W, Xie Q. Modulation of bile acid profile by gut microbiota in chronic hepatitis B. J Cell Mol Med. 2020;24(4):2573\u201381. https:\/\/doi.org\/10.1111\/jcmm.14951.","journal-title":"J Cell Mol Med"},{"key":"5224_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mam.2013.10.001","volume":"37","author":"MJ Pollheimer","year":"2014","unstructured":"Pollheimer MJ, Fickert P, Stieger B. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis. Mol Aspects Med. 2014;37:35\u201356. https:\/\/doi.org\/10.1016\/j.mam.2013.10.001.","journal-title":"Mol Aspects Med"},{"key":"5224_CR36","doi-asserted-by":"publisher","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","volume":"82","author":"S Fiorucci","year":"2021","unstructured":"Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M. Bile acids and their receptors in metabolic disorders. Prog Lipid Res. 2021;82:101094. https:\/\/doi.org\/10.1016\/j.plipres.2021.101094.","journal-title":"Prog Lipid Res"},{"issue":"5","key":"5224_CR37","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1053\/gast.2002.32982","volume":"122","author":"ST Hwang","year":"2002","unstructured":"Hwang ST, Urizar NL, Moore DD, Henning SJ. Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology. 2002;122(5):1483\u201392. https:\/\/doi.org\/10.1053\/gast.2002.32982.","journal-title":"Gastroenterology"},{"issue":"6","key":"5224_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731\u201344. https:\/\/doi.org\/10.1016\/s0092-8674(00)00062-3.","journal-title":"Cell"},{"issue":"1","key":"5224_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/hep.24681","volume":"55","author":"E Studer","year":"2012","unstructured":"Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012;55(1):267\u201376. https:\/\/doi.org\/10.1002\/hep.24681.","journal-title":"Hepatology"},{"key":"5224_CR40","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3389\/fimmu.2020.01149","volume":"11","author":"L Hou","year":"2020","unstructured":"Hou L, Yang L, Chang N, Zhao X, Zhou X, Dong C, et al. Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome. Front Immunol. 2020;11:1149. https:\/\/doi.org\/10.3389\/fimmu.2020.01149.","journal-title":"Front Immunol"},{"key":"5224_CR41","doi-asserted-by":"publisher","unstructured":"Hohenester S, Kanitz V, Kremer AE, Paulusma CC, Wimmer R, Kuehn H, et al. Glycochenodeoxycholate Promotes Liver Fibrosis in Mice with Hepatocellular Cholestasis. Cells. 2020;9(2). https:\/\/doi.org\/10.3390\/cells9020281.","DOI":"10.3390\/cells9020281"},{"issue":"4","key":"5224_CR42","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","volume":"45","author":"C Guo","year":"2016","unstructured":"Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, et al. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. Immunity. 2016;45(4):802\u201316. https:\/\/doi.org\/10.1016\/j.immuni.2016.09.008.","journal-title":"Immunity"},{"issue":"3","key":"5224_CR43","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","volume":"318","author":"JYL Chiang","year":"2020","unstructured":"Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020;318(3):G554\u201373. https:\/\/doi.org\/10.1152\/ajpgi.00223.2019.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"5224_CR44","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.30513","volume":"70","author":"JM Ferrell","year":"2019","unstructured":"Ferrell JM, Pathak P, Boehme S, Gilliland T, Chiang JYL. Deficiency of Both Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice. Hepatology. 2019;70(3):955\u201370. https:\/\/doi.org\/10.1002\/hep.30513.","journal-title":"Hepatology"},{"key":"5224_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/164_2019_230","volume":"256","author":"V Keitel","year":"2019","unstructured":"Keitel V, Stindt J, Haussinger D. Bile Acid-Activated Receptors: GPBAR1 (TGR5) and Other G Protein-Coupled Receptors. Handb Exp Pharmacol. 2019;256:19\u201349. https:\/\/doi.org\/10.1007\/164_2019_230.","journal-title":"Handb Exp Pharmacol"},{"issue":"7","key":"5224_CR46","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/apt.13333","volume":"42","author":"P Pavlidis","year":"2015","unstructured":"Pavlidis P, Powell N, Vincent RP, Ehrlich D, Bjarnason I, Hayee B. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther. 2015;42(7):802\u201317. https:\/\/doi.org\/10.1111\/apt.13333.","journal-title":"Aliment Pharmacol Ther"},{"key":"5224_CR47","doi-asserted-by":"publisher","first-page":"829525","DOI":"10.3389\/fimmu.2022.829525","volume":"13","author":"JP Thomas","year":"2022","unstructured":"Thomas JP, Modos D, Rushbrook SM, Powell N, Korcsmaros T. The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease. Front Immunol. 2022;13:829525. https:\/\/doi.org\/10.3389\/fimmu.2022.829525.","journal-title":"Front Immunol"},{"issue":"2","key":"5224_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225\u201335. https:\/\/doi.org\/10.1016\/j.cmet.2013.01.003.","journal-title":"Cell Metab"},{"issue":"2","key":"5224_CR49","doi-asserted-by":"publisher","first-page":"e0228932","DOI":"10.1371\/journal.pone.0228932","volume":"15","author":"J Kwon","year":"2020","unstructured":"Kwon J, Kim B, Lee C, Joung H, Kim BK, Choi IS, et al. Comprehensive amelioration of high-fat diet-induced metabolic dysfunctions through activation of the PGC-1alpha pathway by probiotics treatment in mice. PLoS ONE. 2020;15(2):e0228932. https:\/\/doi.org\/10.1371\/journal.pone.0228932.","journal-title":"PLoS ONE"},{"issue":"1","key":"5224_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.celrep.2014.02.032","volume":"7","author":"C Degirolamo","year":"2014","unstructured":"Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014;7(1):12\u20138. https:\/\/doi.org\/10.1016\/j.celrep.2014.02.032.","journal-title":"Cell Rep"},{"issue":"1","key":"5224_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","volume":"7","author":"JM Ridlon","year":"2016","unstructured":"Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22\u201339. https:\/\/doi.org\/10.1080\/19490976.2015.1127483.","journal-title":"Gut Microbes"},{"issue":"4","key":"5224_CR52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/gut.2010.212159","volume":"60","author":"RM Gadaleta","year":"2011","unstructured":"Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463\u201372. https:\/\/doi.org\/10.1136\/gut.2010.212159.","journal-title":"Gut"},{"key":"5224_CR53","doi-asserted-by":"publisher","first-page":"111036","DOI":"10.1016\/j.biopha.2020.111036","volume":"133","author":"L Wu","year":"2021","unstructured":"Wu L, Feng J, Li J, Yu Q, Ji J, Wu J, et al. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother. 2021;133:111036. https:\/\/doi.org\/10.1016\/j.biopha.2020.111036.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5224_CR54","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41467-022-30712-x","volume":"13","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Zhuo LB, He Y, Fu Y, Shen L, Xu F, et al. The gut microbiota-bile acid axis links the positive association between chronic insomnia and cardiometabolic diseases. Nat Commun. 2022;13(1):3002. https:\/\/doi.org\/10.1038\/s41467-022-30712-x.","journal-title":"Nat Commun"},{"issue":"7","key":"5224_CR55","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1194\/jlr.M075713","volume":"58","author":"AWF Janssen","year":"2017","unstructured":"Janssen AWF, Houben T, Katiraei S, Dijk W, Boutens L, van der Bolt N, et al. Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. J Lipid Res. 2017;58(7):1399\u2013416. https:\/\/doi.org\/10.1194\/jlr.M075713.","journal-title":"J Lipid Res"},{"issue":"12","key":"5224_CR56","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/hep4.1778","volume":"5","author":"J Iwamoto","year":"2021","unstructured":"Iwamoto J, Honda A, Miyazaki T, Monma T, Ueda H, Morishita Y, et al. Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human-Like Bile Acid Composition. Hepatol Commun. 2021;5(12):2052\u201367. https:\/\/doi.org\/10.1002\/hep4.1778.","journal-title":"Hepatol Commun"},{"issue":"1","key":"5224_CR57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/fsn3.2007","volume":"9","author":"X Yu","year":"2021","unstructured":"Yu X, Xue M, Liu Y, Zhou Z, Jiang Y, Sun T, et al. Effect of nicotinamide riboside on lipid metabolism and gut microflora-bile acid axis in alcohol-exposed mice. Food Sci Nutr. 2021;9(1):429\u201340. https:\/\/doi.org\/10.1002\/fsn3.2007.","journal-title":"Food Sci Nutr"},{"key":"5224_CR58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev-med-111717-122956","volume":"70","author":"RE Ooijevaar","year":"2019","unstructured":"Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical Application and Potential of Fecal Microbiota Transplantation. Annu Rev Med. 2019;70:335\u201351. https:\/\/doi.org\/10.1146\/annurev-med-111717-122956.","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"5224_CR59","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jfma.2018.08.011","volume":"118","author":"JW Wang","year":"2019","unstructured":"Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019;118(Suppl 1):S23\u201331. https:\/\/doi.org\/10.1016\/j.jfma.2018.08.011.","journal-title":"J Formos Med Assoc"},{"key":"5224_CR60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fcimb.2019.00454","volume":"9","author":"G Wie\u00ebrs","year":"2019","unstructured":"Wie\u00ebrs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy JM, Dequenne I, et al. How Probiotics Affect the Microbiota. Front Cell Infect Microbiol. 2019;9:454. https:\/\/doi.org\/10.3389\/fcimb.2019.00454.","journal-title":"Front Cell Infect Microbiol"},{"key":"5224_CR61","doi-asserted-by":"publisher","unstructured":"Wang X, Zhang P, Zhang X. Probiotics Regulate Gut Microbiota: An Effective Method to Improve Immunity. Molecules. 2021;26(19). https:\/\/doi.org\/10.3390\/molecules26196076.","DOI":"10.3390\/molecules26196076"},{"issue":"2","key":"5224_CR62","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hep4.1639","volume":"5","author":"JS Bajaj","year":"2021","unstructured":"Bajaj JS, Shamsaddini A, Fagan A, Sterling RK, Gavis E, Khoruts A, et al. Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials. Hepatol Commun. 2021;5(2):258\u201371. https:\/\/doi.org\/10.1002\/hep4.1639.","journal-title":"Hepatol Commun"},{"issue":"5","key":"5224_CR63","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1053\/j.gastro.2013.08.058","volume":"145","author":"LP Smits","year":"2013","unstructured":"Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946\u201353. https:\/\/doi.org\/10.1053\/j.gastro.2013.08.058.","journal-title":"Gastroenterology"},{"issue":"4","key":"5224_CR64","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ajg.2013.4","volume":"108","author":"CM Surawicz","year":"2013","unstructured":"Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478\u201398. https:\/\/doi.org\/10.1038\/ajg.2013.4. quiz 99.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"5224_CR65","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-019-0439-x","volume":"25","author":"J Suez","year":"2019","unstructured":"Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716\u201329. https:\/\/doi.org\/10.1038\/s41591-019-0439-x.","journal-title":"Nat Med"},{"issue":"4","key":"5224_CR66","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhin.2017.04.007","volume":"96","author":"Y Kang","year":"2017","unstructured":"Kang Y, Cai Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect. 2017;96(4):342\u20138. https:\/\/doi.org\/10.1016\/j.jhin.2017.04.007.","journal-title":"J Hosp Infect"},{"issue":"4","key":"5224_CR67","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/hep.30037","volume":"68","author":"JS Bajaj","year":"2018","unstructured":"Bajaj JS, Kakiyama G, Savidge T, Takei H, Kassam ZA, Fagan A, et al. Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. Hepatology. 2018;68(4):1549\u201358. https:\/\/doi.org\/10.1002\/hep.30037.","journal-title":"Hepatology"},{"key":"5224_CR68","doi-asserted-by":"publisher","first-page":"844374","DOI":"10.3389\/fnut.2022.844374","volume":"9","author":"F Sabirin","year":"2022","unstructured":"Sabirin F, Lim SM, Neoh CF, Ramasamy K. Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. Front Nutr. 2022;9:844374. https:\/\/doi.org\/10.3389\/fnut.2022.844374.","journal-title":"Front Nutr"},{"key":"5224_CR69","doi-asserted-by":"publisher","unstructured":"Xie C, Halegoua-DeMarzio D. Role of Probiotics in Non-alcoholic Fatty Liver Disease. Does Gut Microbiota Matter? Nutrients. 2019;11(11). https:\/\/doi.org\/10.3390\/nu11112837.","DOI":"10.3390\/nu11112837"},{"issue":"1","key":"5224_CR70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3164\/jcbn.11-38","volume":"50","author":"RY Xu","year":"2012","unstructured":"Xu RY, Wan YP, Fang QY, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 2012;50(1):72\u20137. https:\/\/doi.org\/10.3164\/jcbn.11-38.","journal-title":"J Clin Biochem Nutr"},{"key":"5224_CR71","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhang Y, Yang J, Li H, Wang J, Geng W. Lactobacillus plantarum MA2 Ameliorates Methionine and Choline-Deficient Diet Induced Non-Alcoholic Fatty Liver Disease in Rats by Improving the Intestinal Microecology and Mucosal Barrier. Foods. 2021;10(12). https:\/\/doi.org\/10.3390\/foods10123126.","DOI":"10.3390\/foods10123126"},{"issue":"6","key":"5224_CR72","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/hep.30975","volume":"71","author":"Y Liu","year":"2020","unstructured":"Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, et al. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice. Hepatology. 2020;71(6):2050\u201366. https:\/\/doi.org\/10.1002\/hep.30975.","journal-title":"Hepatology"},{"key":"5224_CR73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","volume":"65","author":"M Parola","year":"2019","unstructured":"Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37\u201355. https:\/\/doi.org\/10.1016\/j.mam.2018.09.002.","journal-title":"Mol Aspects Med"},{"issue":"2","key":"5224_CR74","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.32285","volume":"75","author":"SL Friedman","year":"2022","unstructured":"Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology. 2022;75(2):473\u201388. https:\/\/doi.org\/10.1002\/hep.32285.","journal-title":"Hepatology"},{"issue":"1","key":"5224_CR75","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13020-021-00524-0","volume":"16","author":"X Xue","year":"2021","unstructured":"Xue X, Wu J, Ding M, Gao F, Zhou F, Xu B, et al. Si-Wu-Tang ameliorates fibrotic liver injury via modulating intestinal microbiota and bile acid homeostasis. Chin Med. 2021;16(1):112. https:\/\/doi.org\/10.1186\/s13020-021-00524-0.","journal-title":"Chin Med"},{"issue":"3","key":"5224_CR76","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764\u201375. https:\/\/doi.org\/10.1002\/hep.28356.","journal-title":"Hepatology"},{"key":"5224_CR77","doi-asserted-by":"publisher","first-page":"34055","DOI":"10.1038\/srep34055","volume":"6","author":"Y Chen","year":"2016","unstructured":"Chen Y, Ji F, Guo J, Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep. 2016;6:34055. https:\/\/doi.org\/10.1038\/srep34055.","journal-title":"Sci Rep"},{"issue":"7516","key":"5224_CR78","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59\u201364. https:\/\/doi.org\/10.1038\/nature13568.","journal-title":"Nature"},{"issue":"5","key":"5224_CR79","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.dld.2018.02.012","volume":"50","author":"C Binda","year":"2018","unstructured":"Binda C, Lopetuso LR, Rizzatti G, Gibiino G, Cennamo V, Gasbarrini A. Actinobacteria: A relevant minority for the maintenance of gut homeostasis. Dig Liver Dis. 2018;50(5):421\u20138. https:\/\/doi.org\/10.1016\/j.dld.2018.02.012.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"5224_CR80","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/hep.28829","volume":"64","author":"B Lelouvier","year":"2016","unstructured":"Lelouvier B, Servant F, Pa\u00efss\u00e9 S, Brunet AC, Benyahya S, Serino M, et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology. 2016;64(6):2015\u201327. https:\/\/doi.org\/10.1002\/hep.28829.","journal-title":"Hepatology"},{"issue":"5","key":"5224_CR81","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/hep.26695","volume":"59","author":"S De Minicis","year":"2014","unstructured":"De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014;59(5):1738\u201349. https:\/\/doi.org\/10.1002\/hep.26695.","journal-title":"Hepatology"},{"issue":"10","key":"5224_CR82","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jnutbio.2013.05.005","volume":"24","author":"FA Duca","year":"2013","unstructured":"Duca FA, Sakar Y, Covasa M. The modulatory role of high fat feeding on gastrointestinal signals in obesity. J Nutr Biochem. 2013;24(10):1663\u201377. https:\/\/doi.org\/10.1016\/j.jnutbio.2013.05.005.","journal-title":"J Nutr Biochem"},{"issue":"11","key":"5224_CR83","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","volume":"13","author":"E Seki","year":"2007","unstructured":"Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13(11):1324\u201332. https:\/\/doi.org\/10.1038\/nm1663.","journal-title":"Nat Med"},{"issue":"4","key":"5224_CR84","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12072-010-9219-x","volume":"4","author":"JB Soares","year":"2010","unstructured":"Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide\/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int. 2010;4(4):659\u201372. https:\/\/doi.org\/10.1007\/s12072-010-9219-x.","journal-title":"Hepatol Int"},{"issue":"6","key":"5224_CR85","doi-asserted-by":"publisher","first-page":"G1318","DOI":"10.1152\/ajpgi.00405.2005","volume":"290","author":"F Isayama","year":"2006","unstructured":"Isayama F, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry AW, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1318\u201328. https:\/\/doi.org\/10.1152\/ajpgi.00405.2005.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"5224_CR86","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3892\/ol.2017.6762","volume":"14","author":"D Zhang","year":"2017","unstructured":"Zhang D, Hao X, Xu L, Cui J, Xue L, Tian Z. Intestinal flora imbalance promotes alcohol-induced liver fibrosis by the TGF\u03b2\/smad signaling pathway in mice. Oncol Lett. 2017;14(4):4511\u20136. https:\/\/doi.org\/10.3892\/ol.2017.6762.","journal-title":"Oncol Lett"},{"issue":"3","key":"5224_CR87","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1113\/jphysiol.2011.219691","volume":"590","author":"E Seki","year":"2012","unstructured":"Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012;590(3):447\u201358. https:\/\/doi.org\/10.1113\/jphysiol.2011.219691.","journal-title":"J Physiol"},{"issue":"4","key":"5224_CR88","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.32197","volume":"75","author":"SY Kwan","year":"2022","unstructured":"Kwan SY, Jiao J, Joon A, Wei P, Petty LE, Below JE, et al. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology. 2022;75(4):955\u201367. https:\/\/doi.org\/10.1002\/hep.32197.","journal-title":"Hepatology"},{"key":"5224_CR89","doi-asserted-by":"publisher","unstructured":"Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med. 2020;12(572). https:\/\/doi.org\/10.1126\/scitranslmed.aaz2841.","DOI":"10.1126\/scitranslmed.aaz2841"},{"issue":"4","key":"5224_CR90","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/hep.27819","volume":"62","author":"JS Bajaj","year":"2015","unstructured":"Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62(4):1260\u201371. https:\/\/doi.org\/10.1002\/hep.27819.","journal-title":"Hepatology"},{"issue":"7","key":"5224_CR91","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cgh.2013.02.015","volume":"11","author":"M Raman","year":"2013","unstructured":"Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(7):868\u201375. https:\/\/doi.org\/10.1016\/j.cgh.2013.02.015. .e1-3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"5224_CR92","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s1499-3872(17)60019-5","volume":"16","author":"F Shen","year":"2017","unstructured":"Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16(4):375\u201381. https:\/\/doi.org\/10.1016\/s1499-3872(17)60019-5.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"5224_CR93","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","volume":"60","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.019.","journal-title":"J Hepatol"},{"issue":"1","key":"5224_CR94","doi-asserted-by":"publisher","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","volume":"302","author":"JS Bajaj","year":"2012","unstructured":"Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302(1):G168\u201375. https:\/\/doi.org\/10.1152\/ajpgi.00190.2011.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"5224_CR95","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","volume":"54","author":"Y Chen","year":"2011","unstructured":"Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562\u201372. https:\/\/doi.org\/10.1002\/hep.24423.","journal-title":"Hepatology"},{"issue":"8","key":"5224_CR96","doi-asserted-by":"publisher","first-page":"e19248","DOI":"10.1097\/md.0000000000019248","volume":"99","author":"LT Yan","year":"2020","unstructured":"Yan LT, Wang LL, Yao J, Yang YT, Mao XR, Yue W, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. Med (Baltim). 2020;99(8):e19248. https:\/\/doi.org\/10.1097\/md.0000000000019248.","journal-title":"Med (Baltim)"},{"issue":"2","key":"5224_CR97","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2893.2012.01628.x","volume":"20","author":"A Shlomai","year":"2013","unstructured":"Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, et al. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2013;20(2):95\u2013102. https:\/\/doi.org\/10.1111\/j.1365-2893.2012.01628.x.","journal-title":"J Viral Hepat"},{"issue":"1","key":"5224_CR98","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12916-020-01595-w","volume":"18","author":"G Xie","year":"2020","unstructured":"Xie G, Wang X, Wei R, Wang J, Zhao A, Chen T, et al. Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection. BMC Med. 2020;18(1):144. https:\/\/doi.org\/10.1186\/s12916-020-01595-w.","journal-title":"BMC Med"},{"key":"5224_CR99","doi-asserted-by":"publisher","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","volume":"116","author":"N Nimer","year":"2021","unstructured":"Nimer N, Choucair I, Wang Z, Nemet I, Li L, Gukasyan J, et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2021;116:154457. https:\/\/doi.org\/10.1016\/j.metabol.2020.154457.","journal-title":"Metabolism"},{"issue":"1","key":"5224_CR100","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","volume":"11","author":"FG Schaap","year":"2014","unstructured":"Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11(1):55\u201367. https:\/\/doi.org\/10.1038\/nrgastro.2013.151.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"5224_CR101","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.7150\/ijbs.69833","volume":"18","author":"H Xiang","year":"2022","unstructured":"Xiang H, Liu Z, Xiang H, Xiang D, Xiao S, Xiao J, et al. Dynamics of the gut-liver axis in rats with varying fibrosis severity. Int J Biol Sci. 2022;18(8):3390\u2013404. https:\/\/doi.org\/10.7150\/ijbs.69833.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"5224_CR102","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","volume":"176","author":"T Fu","year":"2019","unstructured":"Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, et al. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019;176(5):1098\u2013e11218. https:\/\/doi.org\/10.1016\/j.cell.2019.01.036.","journal-title":"Cell"},{"issue":"2","key":"5224_CR103","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1042\/bj1880321","volume":"188","author":"D Billington","year":"1980","unstructured":"Billington D, Evans CE, Godfrey PP, Coleman R. Effects of bile salts on the plasma membranes of isolated rat hepatocytes. Biochem J. 1980;188(2):321\u20137. https:\/\/doi.org\/10.1042\/bj1880321.","journal-title":"Biochem J"},{"issue":"5","key":"5224_CR104","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.3892\/etm.2019.8011","volume":"18","author":"N Liu","year":"2019","unstructured":"Liu N, Feng J, Lv Y, Liu Q, Deng J, Xia Y, et al. Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study. Exp Ther Med. 2019;18(5):4058\u201366. https:\/\/doi.org\/10.3892\/etm.2019.8011.","journal-title":"Exp Ther Med"},{"issue":"2","key":"5224_CR105","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","volume":"67","author":"P Puri","year":"2018","unstructured":"Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018;67(2):534\u201348. https:\/\/doi.org\/10.1002\/hep.29359.","journal-title":"Hepatology"},{"issue":"3","key":"5224_CR106","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.molmed.2021.12.006","volume":"28","author":"MM Thibaut","year":"2022","unstructured":"Thibaut MM, Bindels LB. Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation. Trends Mol Med. 2022;28(3):223\u201336. https:\/\/doi.org\/10.1016\/j.molmed.2021.12.006.","journal-title":"Trends Mol Med"},{"issue":"4","key":"5224_CR107","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1053\/j.gastro.2005.01.007","volume":"128","author":"G Svegliati-Baroni","year":"2005","unstructured":"Svegliati-Baroni G, Ridolfi F, Hannivoort R, Saccomanno S, Homan M, De Minicis S, et al. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology. 2005;128(4):1042\u201355. https:\/\/doi.org\/10.1053\/j.gastro.2005.01.007.","journal-title":"Gastroenterology"},{"issue":"04","key":"5224_CR108","first-page":"301","volume":"28","author":"Z Yi-ning","year":"2010","unstructured":"Yi-ning Z, Ikegami T, Hong-wei D, Matsuzaki Y. Bile acids enhance proliferation and motility of hepatic stellate cell through regulation of p38 \u0f0fJNK signaling. J Clin Pediatr. 2010;28(04):301\u20136.","journal-title":"J Clin Pediatr"},{"issue":"9","key":"5224_CR109","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1128\/aem.70.9.5603-5612.2004","volume":"70","author":"GB Kim","year":"2004","unstructured":"Kim GB, Miyamoto CM, Meighen EA, Lee BH. Cloning and characterization of the bile salt hydrolase genes (bsh) from Bifidobacterium bifidum strains. Appl Environ Microbiol. 2004;70(9):5603\u201312. https:\/\/doi.org\/10.1128\/aem.70.9.5603-5612.2004.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"5224_CR110","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40168-019-0628-3","volume":"7","author":"Z Song","year":"2019","unstructured":"Song Z, Cai Y, Lao X, Wang X, Lin X, Cui Y, et al. Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome. Microbiome. 2019;7(1):9. https:\/\/doi.org\/10.1186\/s40168-019-0628-3.","journal-title":"Microbiome"},{"issue":"7","key":"5224_CR111","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/cid\/ciy149","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical infectious diseases: an official publication of the Infectious Diseases. Soc Am. 2018;66(7):987\u201394. https:\/\/doi.org\/10.1093\/cid\/ciy149.","journal-title":"Soc Am"},{"issue":"3","key":"5224_CR112","first-page":"612","volume":"18","author":"MR Nicholson","year":"2020","unstructured":"Nicholson MR, Mitchell PD, Alexander E, Ballal S, Bartlett M, Becker P, et al. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterological Association. 2020;18(3):612\u20139. e1.","journal-title":"J Am Gastroenterological Association"},{"issue":"10","key":"5224_CR113","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/ecco-jcc\/jjz060","volume":"13","author":"A Sood","year":"2019","unstructured":"Sood A, Mahajan R, Singh A, Midha V, Mehta V, Narang V, et al. Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study. J Crohn\u2019s colitis. 2019;13(10):1311\u20137. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz060.","journal-title":"J Crohn\u2019s colitis"},{"issue":"1","key":"5224_CR114","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1038\/s41598-017-04984-z","volume":"7","author":"Z He","year":"2017","unstructured":"He Z, Li P, Zhu J, Cui B, Xu L, Xiang J, et al. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn\u2019s disease complicated with inflammatory mass. Sci Rep. 2017;7(1):4753. https:\/\/doi.org\/10.1038\/s41598-017-04984-z.","journal-title":"Sci Rep"},{"issue":"8630","key":"5224_CR115","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(89)91183-5","volume":"1","author":"JD Bennet","year":"1989","unstructured":"Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet (London England). 1989;1(8630):164. https:\/\/doi.org\/10.1016\/s0140-6736(89)91183-5.","journal-title":"Lancet (London England)"},{"issue":"1","key":"5224_CR116","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1053\/j.gastro.2021.09.061","volume":"162","author":"SF Lima","year":"2022","unstructured":"Lima SF, Gogokhia L, Viladomiu M, Chou L, Putzel G, Jin WB, et al. Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation. Gastroenterology. 2022;162(1):166\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.061.","journal-title":"Gastroenterology"},{"issue":"6","key":"5224_CR117","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/hep.29306","volume":"66","author":"JS Bajaj","year":"2017","unstructured":"Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology (Baltimore MD). 2017;66(6):1727\u201338. https:\/\/doi.org\/10.1002\/hep.29306.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"7","key":"5224_CR118","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","volume":"115","author":"L Craven","year":"2020","unstructured":"Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol. 2020;115(7):1055\u201365. https:\/\/doi.org\/10.14309\/ajg.0000000000000661.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"5224_CR119","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3350\/cmh.2020.0057","volume":"26","author":"SM Shasthry","year":"2020","unstructured":"Shasthry SM. Fecal microbiota transplantation in alcohol related liver diseases. Clin Mol Hepatol. 2020;26(3):294\u2013301. https:\/\/doi.org\/10.3350\/cmh.2020.0057.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"5224_CR120","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","volume":"16","author":"A Sharma","year":"2022","unstructured":"Sharma A, Roy A, Premkumar M, Verma N, Duseja A, Taneja S, et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hep Intl. 2022;16(2):433\u201346. https:\/\/doi.org\/10.1007\/s12072-022-10312-z.","journal-title":"Hep Intl"},{"issue":"2","key":"5224_CR121","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1053\/j.gastro.2016.10.012","volume":"152","author":"RB Sartor","year":"2017","unstructured":"Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology. 2017;152(2):327 https:\/\/doi.org\/10.1053\/j.gastro.2016.10.012.","journal-title":"Gastroenterology"},{"key":"5224_CR122","doi-asserted-by":"publisher","first-page":"929346","DOI":"10.3389\/fmicb.2022.929346","volume":"13","author":"H-Z Gou","year":"2022","unstructured":"Gou H-Z, Zhang Y-L, Ren L-F, Z-J L LZ. How do intestinal probiotics restore the intestinal barrier\u0f1f. Front Microbiol. 2022;13:929346. https:\/\/doi.org\/10.3389\/fmicb.2022.929346.","journal-title":"Front Microbiol"},{"issue":"1","key":"5224_CR123","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/s0007114516004037","volume":"117","author":"PA Bron","year":"2017","unstructured":"Bron PA, Kleerebezem M, Brummer RJ, Cani PD, Mercenier A, MacDonald TT, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr. 2017;117(1):93\u2013107. https:\/\/doi.org\/10.1017\/s0007114516004037.","journal-title":"Br J Nutr"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-026-05224-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-05224-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-05224-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:38:31Z","timestamp":1786491511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-026-05224-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5224"],"URL":"https:\/\/doi.org\/10.1186\/s12866-026-05224-z","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments and procedures were approved by the Laboratory Animal Ethics Committee of Lanzhou University (ethics approval number: LDYYLL2023-294). This study involves animal experiments only and is not a clinical trial involving human participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"716"}}